Eli Lilly's weight-loss drug could generate billions in sales
Summary: Eli Lilly's new weight-loss drug could generate over $62 billion in 2030 sales, with a potential increase to $81 billion when factoring in next-generation drugs. Analyst Geoff Meacham raised the stock's price target to 1,000, citing a competitive advantage over rivals. Eli Lilly and Novo Nordisk lead the obesity treatment space, with a projected 7% of U.S. adults using GLP-1 agonist drugs for weight loss by 2030. The stock has a 29% year-to-date increase and a Relative Strength Rating of 95.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
We analyze up to 10,000 news articles daily and find the most significant world news.
Read more about how we calculate significance, or see today's top rated news on the main page:
See today's news rankings